+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 70 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.

Age: 18Years +All GendersPhase 2
38 locations
E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
P

Actively Recruiting

Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.

Age: 18Years +All GendersPhase 1
45 locations
P

Actively Recruiting

Researchers are studying MEN2501, an oral drug, in adults with platinum-resistant ovarian cancer including high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. This first-in-human, open-label trial aims to assess the safety, tolerability, how the drug moves through the body, its effects, and antitumor activity. The study is conducted in two parts dose escalation and dose expansionoptimization. In Part A, participants receive increasing doses of MEN2501 to evaluate dose-limiting toxicities during the first 28-day cycle. Part B focuses on determining the recommended phase 2 dose over approximately six months. The drug is given orally as tablets. The trial uses a sequential study model with randomized allocation and no masking. Participants will be monitored for treatment-emergent adverse events, tumor response rates, duration of response, clinical benefit, progression-free survival, overall survival, and drug concentration levels. These assessments occur over periods ranging from about six to twelve months. The total study duration extends to June 2028, with ongoing safety and efficacy follow-up through primary and secondary outcome measures.

Age: 18Years +FEMALEPhase 1
15 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
E

Actively Recruiting

Researchers are evaluating how well protective immunity from routine childhood vaccinations lasts in children and young adults under 21 years old who have been treated for B-cell Acute Lymphoblastic LeukemiaLymphoma B-ALLLy, particularly focusing on those who received the immunotherapy drug blinatumomab. The study aims to find out if immunotherapy affects vaccine protection compared to other chemotherapy treatments and whether revaccination can restore immunity in those with low antibody levels. This observational study compares participants who have received blinatumomab with those who have not. It examines their antibody levels to common childhood vaccines to assess immunity persistence. For those without protective antibody levels, revaccination is given to see if it improves immune response. The study does not involve active treatment but collects data on immunity status and revaccination effects. Participants will be followed for at least six months after completing blinatumomab therapy to measure protective antibody titers. The study records whether revaccination leads to seroconversion, meaning a change from non-protective to protective antibody levels. Researchers collect blood samples and monitor immune responses without altering standard care. The entire study is expected to run until 2029, with ongoing assessments of immunity and vaccine response in this vulnerable population.

Age: 1Year - 23YearsAll Genders
2 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of JNJ-79635322 compared to teclistamab in adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior treatments, including an anti-CD38 antibody and lenalidomide. This phase 3 randomized study aims to assess how well these treatments work in controlling the disease and improving patient outcomes. Participants will receive subcutaneous injections of either JNJ-79635322 for a limited time or until intolerable side effects occur, or teclistamab as a subcutaneous injection until disease progression or intolerable toxicity. The study compares these two treatment approaches in parallel groups to observe differences in clinical response and safety. During the study, participants will be regularly monitored with laboratory tests and evaluations to measure responses such as complete response, progression-free survival, and quality of life. Researchers will track side effects, symptoms, and functioning over up to approximately 41 months. The study includes detailed assessments using questionnaires and laboratory parameters to understand treatment impact and safety throughout the participation period.

Age: 18Years +All GendersPhase 3
173 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations

1-10 of 70

1